FierceBiotechOriginal article
{"a":[{"_":"Regeneron ends eye disease trial for anti-CD3 antibody following safety review","$":{"href":"/biotech/regeneron-ends-eye-disease-trial-anti-cd3-antibody-following-safety-review","hreflang":"en"}}]}
Phase 1negativeanti-CD3 antibodyNegative
AI Analysis
Summary
Regeneron discontinued a Phase 1/2a trial of an anti-CD3 antibody for eye inflammation following an adverse event that unfavorably altered the drug's risk/benefit profile.
Clinical Trial Data
Phase
1/2a
Primary Endpoint
Not Met
Outcome Details
Trial terminated following adverse event that negatively impacted drug's risk/benefit profile
Importance:6/10
Sentiment:
-0.85
trial terminationsafety concernadverse eventophthalmologyimmunology
Related Companies
Read the original article
Published by FierceBiotech on August 17, 2026 1:55 PM